Autor: Priv.-Doz. Dr. med. Ulrich Germing, Universitätsklinikum Düsseldorf, Düsseldorf
Quellenangabe: Deutsches MDS-Forum - Dresden 2006
Stand: 27.11.2006
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J.
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. PM:9058730
[Medline]
Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C.
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Leukemia 2005;19:2223-2231. PM:16193087
[Medline]
Kündgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U.
Myelodysplastic Syndromes under the age of 50 years.
Journal of Clin Oncol, in press
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M.
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.
J Clin Oncol 2005;23:7594-7603. PM:16186598
[Medline]
Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Ljungman P, Carreras E, Kolb HJ, Aul C, Apperley J.
Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Bone Marrow Transplant 1998;2:255. PM:9489648
[Medline]
Aul C, Runde V, Germing U, Burk M, Heyll A, Hildebrandt B, Willers R.
Remission rates, survival and prognostic factors in 90 patients with advanced MDS treated with intensive chemotherapy.
Haematol Blood Transfus 1997;38:918
Ganser A., Hofmann W.K., Geissler G.
Intensive chemotherapy (Idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML.
Leuk Res 1997;21:174.
Aivado M, Rong A, Germing U, Gattermann N, Kobbe G, Rieth C, Haas R, Aul C.
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
Br J Haematol 2000;110:884. PM:11054075
[Medline]
Knipp S, Hildebrandt B, Giagounidis AAN, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
Intensive chemotherapy is not recommended for patients with AML or high-risk AML aged over 60 years with complex karyotype anomalies.
Blood 2004;104:24.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B.
J Clin Oncol 2002;20:2429-40. PM:12011120
[Medline]
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H.
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Cancer 2006;106:1794-1803. PM:16532500
[Medline]
Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B.
Final results of a phase I/II study of the combination of the hypomethylating agent 5-aza-2'-deoxycytidine (DAC) and the histone deacetylase inhibitor valproic acid (VPA) in patients with leukemia.
Blood 106:123-123. PM:16882711
[Medline]
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB.
Efficacy of lenalidomide in myelodysplastic syndromes.
N Engl J Med 2005;352:549. PM:15703420
[Medline]
Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C.
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Ann Hematol 2005;84:569. PM:15891887
[Medline]
Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N.
Thalidomide for the treatment of patients with myelodysplastic syndromes.
Leukemia 2002;16:1-6. PM:11840256
[Medline]
Kurzrock R, Fenaux P, Raza A, Mufti G, Aul C, Germing U, Kerstens R, DePorre P.
High-risk myelodysplastic syndrome (MDS): First results of international phase 2 study with oral farnesyltransferase inhibitor R115777 (ZARNESTRA (TM)).
Blood 2004;104:23.
[Medline]